EHA 2023

Ibrutinib Improves PFS, Not OS in High-Risk CLL

By

Jonathan Goodman, MPhil

Ibrutinib does not improve overall survival in patients with treatment-naïve chronic lymphocytic leukemia at high risk of progression, a phase 3 trial suggests.

IT and IV Methotrexate Produce Similar CNS Outcomes in DLBCL

By

Jonathan Goodman, MPhil

Rates of CNS relapse are similar in DLBCL patients who receive high-dose IV methotrexate and those who receive IT methotrexate, phase 3 data suggest.

Teclistamab-Talquetamab Combo Rivals CAR-Ts in Rel/Ref Multiple Myeloma

By

Jonathan Goodman, MPhil

Combination treatment with teclistamab and talquetamab has demonstrated activity in patients with relapsed or refractory multiple myeloma.

Ponatinib Plus Chemo May Be New Standard Care in Newly Diagnosed Ph+ ALL

By

Jonathan Goodman, MPhil

A phase 3 trial suggests that ponatinib is more effective than imatinib for patients with newly diagnosed Ph+ acute lymphoblastic leukemia.

All-Oral Triplet Regimen Demonstrates Activity in Acute Promyelocytic Leukemia

By

Jonathan Goodman, MPhil

An all-oral triplet regimen is safe and effective in patients with newly diagnosed acute promyelocytic leukemia, a phase 2 trial suggests.